
Kwality Pharmaceuticals Ltd. (KPL) 52 Week High Streak: Second Straight Session
Updated: 19 Nov 2026 • 9:29 am
Posted by:

Kwality Pharmaceuticals Ltd. 52 Week High Streak has now extended to its second straight session, with the stock touching a fresh 52-week high of Rs 4,274.75 and moving 3.69% across the streak. At 19 November 2026 at 9:22 AM IST, the latest traded price stood at Rs 4,192.50. The latest Univest figures confirm the repeated-high pattern, but they do not establish a company-specific catalyst for the continued move.
Against the previous close of Rs 4,195.25, the stock was slightly lower by Rs 2.75, or 0.07%, after opening at Rs 4,230 and moving between Rs 4,177.10 and Rs 4,274.75. Market capitalisation stood at Rs 4,195.25 crore. For a reader, Kwality Pharmaceuticals Ltd. 52 Week High Streak is less about a single-day print and more about the fact that the stock has kept resetting its yearly high across consecutive sessions.
Kwality Pharmaceuticals Ltd. 52 Week High Streak: Consecutive High Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 4,192.5 |
| Previous Close | Rs 4,195.25 |
| Today's Move | Rs -2.75 (-0.07%) |
| Open | Rs 4,230 |
| High | Rs 4,274.75 |
| Low | Rs 4,177.1 |
| Market Capitalisation | Rs 4,195.25 crore |
Kwality Pharmaceuticals Ltd. (KPL) traded at Rs 4,192.5 versus the previous close of Rs 4,195.25, a fall of 0.07%. The stock opened at Rs 4,230, reached a high of Rs 4,274.75 and touched a low of Rs 4,177.1.
Kwality Pharmaceuticals Ltd. was trading just below the previous close, while still holding close to its fresh yearly peak. The latest traded price of Rs 4,192.50 was marginally below Rs 4,195.25, and the stock moved down by Rs 2.75, or 0.07%, from that level. The day open of Rs 4,230 placed the stock near the upper part of its intraday band from the start.
The range between Rs 4,177.10 and Rs 4,274.75 shows that the latest trade sat well above the low and just under the fresh high. That high is also the new 52-week high, which is the key marker behind this Kwality Pharmaceuticals Ltd. 52 Week High Streak. Market capitalisation at Rs 4,195.25 crore places the company in the same broad value band as several listed pharmaceutical peers in the comparison set, even though the stock is trading at a distinct price level from most of them. For this Kwality Pharmaceuticals Ltd. 52 Week High Streak, the key point is that the repeat high came while the intraday price stayed near the upper end of the day’s band.
What the Repeated 52-Week Highs Show
The repeated-high pattern tells readers that Kwality Pharmaceuticals Ltd. 52 Week High Streak is not a one-off chart event. The stock has now marked a fresh 52-week high on each of the last two sessions, and the streak move of 3.69% is the clearest numerical sign of that extension. The latest high of Rs 4,274.75 is the reference point for the run so far.
What this also shows is what the data does not show. The numbers confirm a multi-session sequence of new one-year highs, but they do not identify a single company-specific trigger behind the move. That is important for readers tracking Kwality Pharmaceuticals Ltd. 52 Week High Streak, because the pattern itself is factual, while the cause remains unconfirmed in the latest market data. The previous event trading date was 18 November 2026, so the high was repeated immediately, rather than after a long gap.
In practical terms, the streak lens is different from a one-day breakout lens. A single fresh high can be a brief price event; a second straight session at a new 52-week high suggests the stock has held that higher reference point for longer, which is the core feature of Kwality Pharmaceuticals Ltd. 52 Week High Streak. The cumulative move is the best way to read the run, not just the latest tick.
Kwality Pharmaceuticals Ltd. (KPL) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 4,195.25 crore |
| P/E Ratio | 45.36x |
| P/B Ratio | 11.29x |
| ROE | 22.67% |
| ROCE | 24.01% |
| EPS | Rs 92.48 |
| Book Value Per Share | Rs 371.43 |
| Dividend Yield | 0% |
Kwality Pharmaceuticals Ltd. (KPL) fundamental metrics show P/E 45.36x, P/B 11.29x, ROE 22.67%, ROCE 24.01%. Taken on their own, these numbers offer context rather than a trading signal.
Kwality Pharmaceuticals Ltd. has a market capitalisation of Rs 4,195.25 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 45.36x, P/B at 11.29x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 22.67% and ROCE of 24.01%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 92.48, book value per share of Rs 371.43, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 30.5x, median ROE of 11.22%, median ROCE of 13.1%. They set out the fundamental picture and are not a rating on the stock.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 45.36x |
| Benchmark Median P/E | 30.5x |
| Benchmark Average P/E | 59.35x |
| Benchmark P/E Range | 2.71x to 1,378.1x |
| Company P/B Ratio | 11.29x |
| Benchmark Median P/B | 2.79x |
| Company ROE | 22.67% |
| Benchmark Median ROE | 11.22% |
| Company ROCE | 24.01% |
| Benchmark Median ROCE | 13.1% |
| Company Market Capitalisation | Rs 4,195.25 crore |
| Benchmark Median Market Cap | Rs 789.48 crore |
Kwality Pharmaceuticals Ltd. (KPL) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Kwality Pharmaceuticals Ltd. (KPL) has a P/E ratio of 45.36x, which is above the benchmark median of 30.5x, a difference of +48.72%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Kwality Pharmaceuticals Ltd. (KPL) has a ROE of 22.67%, which is above the benchmark median of 11.22%, a difference of +102.05%. Kwality Pharmaceuticals Ltd. (KPL) has a ROCE of 24.01%, which is above the benchmark median of 13.1%, a difference of +83.28%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| RPG Life Sciences Ltd. | RPGLIFE | 4,212.57 | 37.86 | 6.03 | 20.28 | 26.99 |
| Gufic Biosciences Ltd. | GUFICBIO | 4,396.39 | 53.09 | 5.99 | 10.14 | 12.56 |
| SMS Pharmaceuticals Ltd. | SMSPHARMA | 4,557.58 | 38.24 | 5.31 | 12.49 | 13.32 |
| Aarti Drugs Ltd. | AARTIDRUGS | 4,589.51 | 20.18 | 2.75 | 13.36 | 12.04 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | 4,706.29 | 109.74 | 4.46 | 17.41 | 18.16 |
Kwality Pharmaceuticals Ltd. (KPL) has a P/E ratio of 45.36x compared with the displayed peer median of 38.24x. The comparison is relative and should not be read as a recommendation. Its ROE of 22.67% compares with a peer median of 13.36% across the companies shown in the table. ROCE stood at 24.01% versus the displayed peer median of 13.32%, providing a capital-efficiency comparison. Kwality Pharmaceuticals Ltd. (KPL) has a market capitalisation of Rs 4,195.25 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Kwality Pharmaceuticals Ltd.
- The stock has set a fresh 52-week high for its second straight session, which is the defining feature of Kwality Pharmaceuticals Ltd. 52 Week High Streak.
- The cumulative move across the streak is 3.69%, which gives the repeated-high pattern a measurable price context.
- The latest high of Rs 4,274.75 is the current reference point for the yearly high run.
- P/E at 45.36 and P/B at 11.29 place the stock above the industry median on both valuation measures.
- ROE of 22.67% and ROCE of 24.01% remain above the industry medians, giving the streak a stronger profitability backdrop than the sector midpoint.
About Kwality Pharmaceuticals Ltd.
Kwality Pharmaceuticals Ltd. operates in the Pharmaceuticals & Drugs industry within the Healthcare sector. For readers tracking Kwality Pharmaceuticals Ltd. 52 Week High Streak, the main context is that this is a listed pharmaceutical company with a market capitalisation of Rs 4,195.25 crore and a valuation profile that is materially above the industry median. The company’s return ratios also sit above the industry centre, which is why the streak is being assessed against both price and fundamentals rather than price alone.
That business context is enough to frame the streak without drifting into unrelated company detail. The key question now is how long the repeated yearly-high pattern can continue and whether the valuation premium remains supported by the current profitability metrics in the listed pharmaceutical universe.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
What does Kwality Pharmaceuticals Ltd. 52 Week High Streak mean?
Ans. It means the stock has marked a fresh 52-week high on consecutive sessions. In this case, Kwality Pharmaceuticals Ltd. has done so for its second straight session, which makes the pattern more notable than a one-day breakout.
How many sessions has Kwality Pharmaceuticals Ltd. made a fresh 52-week high?
Ans. According to the latest market data, the stock has set a fresh 52-week high for two consecutive sessions.,
What is the cumulative move across the streak?
Ans. The cumulative streak change is 3.69%. That figure captures the full move across the repeated-high run better than looking at the latest trade in isolation.
What is the latest 52-week high for Kwality Pharmaceuticals Ltd.?
Ans. The latest fresh 52-week high is Rs 4,274.75. That level is the current reference point for the Kwality Pharmaceuticals Ltd. 52 Week High Streak. The stock moved -0.07% so far today.
Is a company-specific catalyst confirmed for the repeated highs?
Ans. No confirmed company-specific catalyst is established by the latest market data. The numbers confirm the repeated-high pattern, but they do not identify a single reason for it.
How does the valuation look after the streak?
Ans. The stock trades at a P/E of 45.36 and a P/B of 11.29, both above the industry medians. Because the streak does not change earnings or book value, the change in multiples comes from price.
How does Kwality Pharmaceuticals compare with sector medians?
Ans. Its P/E and P/B are above the healthcare industry medians, while ROE and ROCE are also above the medians. That combination gives the streak a stronger profitability base than the sector midpoint, alongside a premium valuation.
How does the stock compare with listed peers?
Ans. Within the displayed peer set, Kwality Pharmaceuticals Ltd. trades above several peers on both P/E and P/B. It remains below Gujarat Themis Biosyn Ltd. on P/E, but it is in the upper valuation band of the group shown.
Track Kwality Pharmaceuticals Ltd. Share Price on Univest
Use Kwality Pharmaceuticals Ltd. (KPL) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Follow Kwality Pharmaceuticals Ltd. 52 Week High Streak closely if you want to monitor how the stock behaves around its fresh yearly high, the latest traded price and the valuation gap versus the industry median. The repeated-high pattern is the main event, while the financial ratios and peer comparisons provide the wider frame for reading the move.
Recent Articles

Cummins India Share Price Slips to Rs 4,005 Near Its 52-Week Low: Margins Squeezed by Commodity Costs While Price Hikes Take a Quarter to Flow Through
18 November 2026

V2 Retail Share Price Plunges 15% to a 52-Week Low of Rs 122.73 Then Rebounds to Close at Rs 141.61: What We Know, What We Do Not and the Numbers to Watch
18 November 2026

Infosys Share Price Falls to Rs 1,108.80, Down 25.4% in a Year: How India's IT Bellwether Lost a Quarter of Its Value and What Investors Should Check Next
18 November 2026

Nifty Bank 62,000: Index Closes at 62,038.65 After a Record 62,442.20, Up 24% From Its April Low as SBI Surges While HDFC Bank and Axis Bank Lag
18 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Cummins India Share Price Slips to Rs 4,005 Near Its 52-Week Low: Margins Squeezed by Commodity Costs While Price Hikes Take a Quarter to Flow Through
V2 Retail Share Price Plunges 15% to a 52-Week Low of Rs 122.73 Then Rebounds to Close at Rs 141.61: What We Know, What We Do Not and the Numbers to Watch
Infosys Share Price Falls to Rs 1,108.80, Down 25.4% in a Year: How India's IT Bellwether Lost a Quarter of Its Value and What Investors Should Check Next
Nifty Bank 62,000: Index Closes at 62,038.65 After a Record 62,442.20, Up 24% From Its April Low as SBI Surges While HDFC Bank and Axis Bank Lag
Mahanadi Coalfields IPO Opens 19 November: Rs 129 to Rs 136 Price Band, Rs 8,981 Crore Offer for Sale and a Coal India Unit Valued at About 8.4 Times Earnings

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





